Comparison of the Clear Coajet Hemostatic effect on EMR and ESD
Not Applicable
Not yet recruiting
- Conditions
- Neoplasms
Recruitment & Eligibility
- Status
- Not yet recruiting
- Sex
- All
- Target Recruitment
- 404
Inclusion Criteria
(1) Men and women between the ages of 18 and 85
(2) A sessile polyp larger than 1.5 cm or a lateral spreading tumor, that is decided to perform endoscopic mucosal resection or endoscopic submucosal dissection
(3) A person who has signed a written informed consent form to participate in this study
Exclusion Criteria
(1) Pedunculated polyp
(2) Patients with Coagulopathy (international normalized ratio >1.5, a partial thromboplastin time >45 s, or a platelet count <80,000/mL)
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clear Coajet effectiveness on hemostasis of intraoperative bleeding during endoscopic mucosal resection or endoscopic submucosal dissection, hemostasis success rate, time taken to hemostasis, In case you need to use other endoscopic devices such as coagulation forceps or hemoclips for additional hemostasis
- Secondary Outcome Measures
Name Time Method Incidence rate of side effects in both groups (such as bleeding and perforation, which are major side effects) should be investigated. Therefore, accompanied symptoms should be investigated such as melena, decreased hemoglobin level of 2 g/dL or more, dizziness, fever, nausea, vomiting, anorexia etc, Delayed bleeding rate within 30 days after resection, Tumor recurrence rate at follow-up endoscopy after 1 year